Avifavir recommended in Russia for treatment of coronavirus, supply of drug to hospitals to start on June 11
MOSCOW. June 3 (Interfax) - The drug Avifavir is included in the latest version of the list of methodical recommendations of the Russian Health Ministry on the prevention, diagnostics and treatment of the new coronavirus infection, the press service for the Russian Direct Investment Fund (RDIF) said.
"The Russian Direct Investment Fund (RDIF), a sovereign fund of the Russian Federation, and Chemrar Group announce the inclusion by the Russian Health Ministry of the drug Avifavir in the most recent, 7th version of the list of methodical recommendations on the prevention, diagnostics and treatment of the new coronavirus infection," RDIF said in a report.
In the methodical recommendations published by the Russian Health Ministry, the active factor of the drug Favipiravir is stated as a drug for the treatment of coronavirus infection.
Avifavir is one of the two drugs in the world registered as an anti-coronavirus drug, the report said. It has proven effective in clinical tests and it blocks the mechanisms of reproduction of coronavirus, the report said. On May 29, the drug received a registration certificate from the Russian Health Ministry and became the world's first drug based on Favipiravir approved for coronavirus treatment.
The inclusion of Avifavir in the methodical recommendations on the prevention, diagnostics and treatment of coronavirus "will help patients across the country to receive therapy using the drug that is currently the most effective in Russia and it will considerably reduce the pressure on the Russian healthcare system by reducing the period of time needed for recovering," RDIF CEO Kirill Dmitriev said.
The first supplies of the drug to Russian hospitals are expected on June 11. Drugs for 60,000 cycles of the treatment of coronavirus patients will be supplied this month.